

**Abstract number:** Euro18A-POS240

**Abstract type:** Poster

**Reference:** This abstract is a part of the EuroPCR 2018 programme, 22-25 May 2018, Paris

**Link:** <https://abstractbook.pconline.com/export/pdf/id/100414>

**Published on:** 15 May 2018

## **Multicentre clinical outcomes of hybrid tapered sirolimus-eluting coronary stent system with biodegradable polymer in long diffuse de novo coronary artery lesions**

PATTED S. V. (1), JAIN P. R. K. (2), JIWANI P. A. (2), SURYAVANSHI S. (3), RAGHU T. R. (4), RAVEESH H. (5), RAJALAKSHMI S. (6), THAKKAR A. (7)

(1) KLE Academy of Higher Education & Research Centre, Belgaum INDIA(2) KIMS Hospitals, Hyderabad INDIA(3) Fortis Escorts Heart Centre, Raipur INDIA(4) Sri Jayadeva Institute of Cardiovascular Sciences & Research, Bengaluru INDIA(5) Sri Jayadeva Institute of Cardiovascular Sciences & Research K.R. Hospital Campus, Mysore INDIA(6) SUT Hospital Pattom, Trivandrum INDIA(7) Meril Life Sciences Pvt. Ltd., Vapi INDIA

**THEME:** Coronary Interventions

**TOPIC(S):** Stents and scaffolds

### **AIMS**

Tapering of coronary arteries is a major challenge observed with long coronary lesions. This study was conducted to investigate the safety and performance of BioMime? Morph tapered sirolimus-eluting coronary stent system (Meril Life Sciences, Pvt. Ltd., Vapi, India) with an ultra-thin cobalt-chromium platform and a biodegradable polymer in real-world long de novo coronary artery lesions.

### **METHODS AND RESULTS**

This was a retrospective, non-randomised, multi-centre study conducted in 362 patients with long diffuse coronary artery lesions who were implanted with BioMime Morph. The major clinical end-point was major adverse cardiac events (MACE), which is a composite of cardiac death, myocardial infarction (MI), ischemia driven-target lesion revascularization (ID-TLR) at 30-day, and 6-month follow-up period. The mean age of patients was  $61.09 \pm 9.04$  years with signs and symptoms of stable angina, unstable angina, STEMI or NSTEMI. Out of 362 patients, 170 (46.9%) were diabetics and 159 (43.9%) had hypertension. A total of 627 lesions were intervened successfully with 402 stents (1.11 stent per patient). The incidence of MACE was 1 (0.29%) and 4 (1.19%) at 30-day and 6-month follow-up respectively. There was 1 (0.30%) case of MI and ID-TLR, and 2 (0.59%) cases of cardiac death were reported at 6-month follow-up. In addition, 1 (0.30%) patients presented acute stent thrombosis.

### **CONCLUSIONS**

The BioMime Morph tapered coronary stent system demonstrated the safety and performance in real-world patients with long diffuse de novo coronary artery lesions.